HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.

Abstract
Success of cancer vaccination is strongly hampered by immune suppression in the tumor microenvironment (TME). Interleukin (IL)-6 is particularly and highly produced by triple-negative breast cancer (TNBC) cells, and has been considered as an important contributor to immune suppression in the TME. Therefore, we hypothesized that IL-6 reduction may improve efficacy of vaccination against TNBC cancer through improved T-cell responses. To prove this hypothesis, we investigated the effect of curcumin, an inhibitor of IL-6 production, on vaccination of a highly attenuated Listeria monocytogenes (Listeria(at)), encoding tumor-associated antigens (TAA) Mage-b in a TNBC model 4T1. Two therapeutic vaccination strategies with Listeria(at)-Mage-b and curcumin were tested. The first immunization strategy involved all Listeria(at)-Mage-b vaccinations and curcumin after tumor development. As curcumin has been consumed all over the world, the second immunization strategy involved curcumin before and all therapeutic vaccinations with Listeria(at)-Mage-b after tumor development. Here, we demonstrate that curcumin significantly improves therapeutic efficacy of Listeria(at)-Mage-b with both immunization strategies particularly against metastases in a TNBC model (4T1). The combination therapy was slightly but significantly more effective against the metastases when curcumin was administered before compared to after tumor development. With curcumin before tumor development in the combination therapy, the production of IL-6 was significantly decreased and IL-12 increased by myeloid-derived suppressor cells (MDSC), in correlation with improved CD4 and CD8 T-cell responses in blood. Our study suggests that curcumin improves the efficacy of Listeria(at)-Mage-b vaccine against metastases in TNBC model 4T1 through reversal of tumor-induced immune suppression.
AuthorsManisha Singh, Ilyssa Ramos, Denise Asafu-Adjei, Wilber Quispe-Tintaya, Dinesh Chandra, Arthee Jahangir, Xingxing Zang, Bharat B Aggarwal, Claudia Gravekamp
JournalCancer medicine (Cancer Med) Vol. 2 Issue 4 Pg. 571-82 (Aug 2013) ISSN: 2045-7634 [Electronic] United States
PMID24156030 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Bacterial Vaccines
  • Cancer Vaccines
  • Interleukin-6
  • Interleukin-12
  • Curcumin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, pharmacology)
  • Apoptosis (drug effects, immunology)
  • Bacterial Vaccines (administration & dosage, immunology)
  • Cancer Vaccines (administration & dosage, immunology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Curcumin (administration & dosage, pharmacology)
  • Disease Models, Animal
  • Female
  • Immunization
  • Interleukin-12 (biosynthesis)
  • Interleukin-6 (biosynthesis)
  • Listeria monocytogenes (immunology)
  • Mammary Neoplasms, Experimental
  • Mice
  • Myeloid Cells (drug effects, immunology, metabolism)
  • Neoplasm Metastasis
  • T-Lymphocyte Subsets (immunology, metabolism)
  • Triple Negative Breast Neoplasms (immunology, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: